Condition
RARE DISEASE
Total Trials
4
Recruiting
2
Active
2
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 100/100
Termination Rate
25.0%
1 terminated out of 4 trials
Success Rate
0.0%
-86.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
0
Data Visualizations
Phase Distribution
1Total
P 2 (1)
Trial Status
Recruiting2
Terminated1
Enrolling By Invitation1
Clinical Trials (4)
Showing 4 of 4 trials
NCT02938793Phase 2Terminated
Durvalumab in Combination With Tremelimumab in Subjects With Advanced Rare Solid Tumors
NCT07147465Recruiting
Performance Indicators and Impact on the Care Pathway of Sequencing on the SeqOIA and AURAGEN (Seqogen) Platforms for Oncology Patients
NCT05203250Recruiting
Longitudinal Registry Including Patients Treated With Heavy Particles
NCT01440218Enrolling By InvitationPrimary
Idiopathic Diseases of Man
Showing all 4 trials